A) Multidrug treatment using existing medicines early in the symptomatic phase of COVID-19 can dramatically reduce the risk of hospitalization and death [1][2][3]. Coming from front-line doctors actually treating COVID-19 patients, and highly educated and published researchers, this is the most cited literature on the topic that does not concern vaccines.

B) Naturally infected individuals who have recovered acquire robust and durable immunity, and are unlikely to benefit from subsequent vaccination [4][5][6][7].

C) Mandatory nonpharmaceutical interventions such as masks and quarantine may lead to particularly devastating seasons of endemic illnesses such as influenza and RSV [8]. This may further strain medical and healthcare facilities and affect our ability to mitigate the pandemic.

D) Compulsory mass vaccination - combined with vaccines that do not necessarily prevent infection and transmission - may cause selective pressure that further enhances the fitness of the virus [9][10][11][12][13][14][15]. This can lead to partial or complete immune escape which manifests as increased transmission or virulence, reduced vaccine efficacy, and reduced protection in individuals with naturally acquired immunity.

[1] Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection https://www.amjmed.com/article/S0002-9343(20)30673-2/fulltex...

[2] Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) https://scholarlycommons.henryford.com/cgi/viewcontent.cgi?a...

[3] Peter McCullough, MD testifies to Texas Senate HHS Committee https://www.youtube.com/watch?v=QAHi3lX3oGM

[4] SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans https://www.nature.com/articles/s41586-021-03647-4.pdf

[5] Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells https://www.cell.com/cell-reports-medicine/fulltext/S2666-37...

[6] Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920668/

[7] Necessity of COVID-19 vaccination in previously infected individuals https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v...

[8] The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections https://www.pnas.org/content/117/48/30547

[9] Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein https://pubmed.ncbi.nlm.nih.gov/33909660/

[10] SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern https://science.sciencemag.org/content/early/2021/06/30/scie...

[11] mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants https://www.nature.com/articles/s41586-021-03324-6

[12] Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization https://www.nature.com/articles/s41586-021-03777-9

[13] The adaptive evolution of virulence: a review of theoretical predictions and empirical tests https://pubmed.ncbi.nlm.nih.gov/26302775/

[14] Why does drug resistance readily evolve but vaccine resistance does not? https://royalsocietypublishing.org/doi/pdf/10.1098/rspb.2016...

[15] Imperfect Vaccination Can Enhance the Transmission of Highly Virulent Pathogens https://journals.plos.org/plosbiology/article?id=10.1371%2Fj...